Research programme: antisense drug therapies - Ionis/XenonAlternative Names: XEN 701
Latest Information Update: 24 Dec 2015
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Xenon Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Hepcidin inhibitors; HFE2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anaemia